Explore Stanford technologies available for licensing:

Stanford researchers have developed a new technology, Variant-FlowFISH, to enable high-throughput, highly sensitive measurements of how variants, introduced via CRISPR, affect gene expression.

Stanford researchers have developed novel technology that combines AAVMYO, a muscle cell targeting viral vector, with CRISPR base editors to achieve targeted gene repair, showcasing over 70% correction of hereditary mutations in cardiomyocytes.

To overcome current gene editing safety, efficacy, and scope limitations, Stanford researchers in the Mackall Lab and Stanley Qi Lab developed MEGA (Multiplexed Effector Guide Arrays), a versatile and multifunctional platform for programmable and scalable regulation of the T c

Stanford researchers have developed a new methodology called transcript-informed single-cell CRISPR sequencing (TISCC-Seq), for the direct detection and phenotyping of genetic variants in a high-throughput manner.

Researchers at Stanford have identified the use of the drug verteporfin to treat or reduce the risk of developing ibrosis after ocular procedures or ocular injury. Of interest is corneal injury, for example after refractive surgery or crosslinking, e.g.

Researchers at Stanford have developed innovative Verteporfin conjugates that considerably enhance the solubility and therapeutic potential of Verteporfin.

Introduction: Blood cell transfusion plays a vital role in modern medicine–supporting surgery, obstetrics, trauma care, and cancer chemotherapy. In the US alone, more than 12 million red-cell units are consumed annually.

Stanford scientists have discovered that using silent mutations to alter codon:anticodon affinity can be used to tune clonal expansion in CD8 T cells.

Researchers at Stanford University have discovered a novel way of treating dry age-related macular degeneration by inhibiting a causal disease target.

Researchers at Stanford and the European Molecular Biology Laboratory (EMBL) have discovered an improved embodiment of bacterial retron-based CRISPR gene editing in mammalian cells.

Researchers at Stanford have discovered long sought after light gated potassium selective channelrhodopsins., HcKCR1 and HcKCR2.

Researchers at Stanford have demonstrated the first method of its kind for treating cystic fibrosis (CF) using regenerated airway stem cells embedded on a biocompatible scaffold.

Researchers at Stanford have developed a potentially curative treatment strategy for alpha-thalassemia, one of the most common autosomal recessive disorders in the world involving the genes HBA1 and/or HBA2.

Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.

Stanford inventors have developed the CasKAS method for profiling CRISPR off-targets using single-stranded DNA (ssDNA) mapping. Binding of CRISPR protein to DNA generates ssDNA structures, which can be a sensitive biochemical signal of CRISPR occupancy.